Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)


Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment

Media Outlets Highlight Agreement between Renovacor, Inc., a Company Formed to Commercialize Technology Developed at the Lewis Katz School of Medicine, and Chardan Healthcare Acquisition 2 Corp.

View All News

Renovacor, Inc., an early stage biotechnology company founded by Arthur M. Feldman, MD, PhD, Laura H. Carnell Professor of Medicine and Professor in the Center for Translational Medicine at the Lewis Katz School of Medicine at Temple University, and Chardan Healthcare Acquisition 2 Corp., a special purpose acquisition company sponsored by affiliates of Chardan Capital Markets, announced that they have entered into a definitive business combination agreement. Renovacor is developing adeno-associated virus-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene dysfunction. The foundational understanding of BAG3 mutations and the company’s gene therapy product are based on 10 years of Dr. Feldman’s research. Multiple media outlets, including the Philadelphia Business Journal, Markets Insider and Morningstar, highlighted the agreement.